Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director · Chief Executive Officer | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectJoseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 | 2,565,489 |
Last balance in matching sequence
After 2026-06-01 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-05-29 · Gift · Disposed 300,000 · Balance 2,578,326 F1: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Row 4 · 2026-06-01 · Sale · Disposed 12,837 · Balance 2,565,489 F6: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F1: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectJoseph K. Belanoff 2026 Grantor Retained Annuity Trust | 150,000 |
Reported balance
After 2026-05-29 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-05-29 · Gift · Acquired 150,000 · Balance 150,000 F2: Transfer of shares without consideration to the Joseph K. Belanoff 2026 Grantor Retained Annuity Trust. F3: Shares are held by Joseph K. Belanoff 2026 Grantor Retained Annuity Trust, of which the Reporting Person is the trustee. |
| Common StockSEC Table I · non-derivative | IndirectKatherine A. Blenko 2026 Grantor Retained Annuity Trust | 150,000 |
Reported balance
After 2026-05-29 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-05-29 · Gift · Acquired 150,000 · Balance 150,000 F4: Transfer of shares without consideration to the Katherine A. Blenko 2026 Grantor Retained Annuity Trust. F5: Shares are held by Katherine A. Blenko 2026 Grantor Retained Annuity Trust, of which the spouse of the Reporting Person is the trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
F2: Transfer of shares without consideration to the Joseph K. Belanoff 2026 Grantor Retained Annuity Trust.
F3: Shares are held by Joseph K. Belanoff 2026 Grantor Retained Annuity Trust, of which the Reporting Person is the trustee.
F4: Transfer of shares without consideration to the Katherine A. Blenko 2026 Grantor Retained Annuity Trust.
F5: Shares are held by Katherine A. Blenko 2026 Grantor Retained Annuity Trust, of which the spouse of the Reporting Person is the trustee.
F6: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 2, 2026 20:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 12,837 | $69.74 | $895,252.38 |
DisclosureSEC source: 0001193125-26-253459 · ownership.xml · nonDerivative · entry 4 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,565,489 F6 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F1 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-253459 · ownership.xml · nonDerivative · entry 3 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Katherine A. Blenko 2026 Grantor Retained Annuity Trust Disclosed balance after: 150,000 F4 · kind: Transfer of shares without consideration to the Katherine A. Blenko 2026 Grantor Retained Annuity Trust. F5 · ownership.nature: Shares are held by Katherine A. Blenko 2026 Grantor Retained Annuity Trust, of which the spouse of the Reporting Person is the trustee. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-253459 · ownership.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff 2026 Grantor Retained Annuity Trust Disclosed balance after: 150,000 F2 · kind: Transfer of shares without consideration to the Joseph K. Belanoff 2026 Grantor Retained Annuity Trust. F3 · ownership.nature: Shares are held by Joseph K. Belanoff 2026 Grantor Retained Annuity Trust, of which the Reporting Person is the trustee. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-253459 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,578,326 F1 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 40,000 | $50.10 | $2,003,860.00 |
DisclosureSEC source: 0001193125-26-206540 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,878,326 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.00 to $50.35 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 20:27 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 26,198 | $50.07 | $1,311,825.55 |
DisclosureSEC source: 0001193125-26-129143 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,918,326 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.00 to $50.32 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:17 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (right to buy) · Derivative | 460,000 | $0.00 Strike: $35.70 | $0.00 |
DisclosureSEC source: 0001193125-26-089023 · ownership.xml · derivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 460,000 Underlying: Common Stock · 460,000 shares Expires 2036-02-27 F1 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| December 24, 2025 Filed Dec 29, 2025 22:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 550,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001193125-25-335538 · ownership.xml · derivative · entry 5 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 550,000 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 24, 2025 Filed Dec 29, 2025 22:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 243,154 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-335538 · ownership.xml · nonDerivative · entry 4 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,944,524 F2 · kind: Transfer of shares without consideration to the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| December 24, 2025 Filed Dec 29, 2025 22:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 243,154 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-335538 · ownership.xml · nonDerivative · entry 3 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 24, 2025 Filed Dec 29, 2025 22:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 306,846 | $83.59 | $25,649,257.14 |
DisclosureSEC source: 0001193125-25-335538 · ownership.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,154 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability from a net (cashless) exercise of options. Read SEC document |
| December 24, 2025 Filed Dec 29, 2025 22:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 550,000 | $3.88 | $2,134,000.00 |
DisclosureSEC source: 0001193125-25-335538 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 40,000 | $79.77 | $3,190,796.00 |
DisclosureSEC source: 0001193125-25-307204 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,701,370 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.65 to $79.97 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 3,590 | $75.98 | $272,759.94 |
DisclosureSEC source: 0001193125-25-267545 · ownership.xml · nonDerivative · entry 4 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,741,370 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F6 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $75.725 to $76.28 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 10,837 | $75.14 | $814,261.84 |
DisclosureSEC source: 0001193125-25-267545 · ownership.xml · nonDerivative · entry 3 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,744,960 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $74.72 to $75.71 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 14,355 | $74.20 | $1,065,083.58 |
DisclosureSEC source: 0001193125-25-267545 · ownership.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,755,797 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.72 to $74.70 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| November 03, 2025 Filed Nov 6, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 11,218 | $74.08 | $831,013.73 |
DisclosureSEC source: 0001193125-25-267545 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,770,152 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.74 to $74.26 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 3,194 | $85.67 | $273,617.84 |
DisclosureSEC source: 0001193125-25-230467 · ownership.xml · nonDerivative · entry 3 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,781,370 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $85.63 to $85.785 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 31,190 | $85.16 | $2,656,265.16 |
DisclosureSEC source: 0001193125-25-230467 · ownership.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,784,564 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $84.5875 to $85.575 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,616 | $84.29 | $473,369.83 |
DisclosureSEC source: 0001193125-25-230467 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,815,754 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.58 to $84.53 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 700 | $71.01 | $49,707.49 |
DisclosureSEC source: 0001193125-25-196313 · ownership.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,821,370 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.97 to $71.085 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 39,300 | $70.52 | $2,771,325.96 |
DisclosureSEC source: 0001193125-25-196313 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,822,070 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.97 to $70.96 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 22:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,446 | $69.65 | $379,304.64 |
DisclosureSEC source: 0000950170-25-103323 · ownership.xml · nonDerivative · entry 3 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,861,370 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.4412 to $69.77 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 22:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 17,809 | $68.87 | $1,226,486.24 |
DisclosureSEC source: 0000950170-25-103323 · ownership.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,866,816 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $68.43 to $69.42 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 22:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 16,745 | $67.81 | $1,135,416.49 |
DisclosureSEC source: 0000950170-25-103323 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,884,625 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $67.42 to $68.33 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 23:11 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 615 | $73.69 | $45,317.69 |
DisclosureSEC source: 0000950170-25-097372 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,901,370 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.655 to $73.74 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 8,408 | $85.01 | $714,777.53 |
DisclosureSEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 8 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,901,985 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F10 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $85.00 to $85.31 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 12,959 | $84.57 | $1,095,962.07 |
DisclosureSEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 7 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,910,393 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F9 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.975 to $84.94 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 4,631 | $83.46 | $386,523.17 |
DisclosureSEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 6 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,923,352 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F8 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $82.96 to $83.95 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 1,263 | $82.26 | $103,898.67 |
DisclosureSEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 5 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,927,983 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F7 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.935 to $82.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 1,820 | $81.33 | $148,012.41 |
DisclosureSEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 4 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,929,246 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F6 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.92 to $81.78 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 2,988 | $80.30 | $239,941.48 |
DisclosureSEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 3 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,931,066 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.90 to $80.8925 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 3,050 | $79.48 | $242,421.02 |
DisclosureSEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,934,054 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $78.88 to $79.865 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 00:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 4,881 | $78.42 | $382,773.39 |
DisclosureSEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,937,104 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $77.84 to $78.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 02, 2025 Filed May 6, 2025 00:28 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 21,520 | $73.22 | $1,575,776.18 |
DisclosureSEC source: 0000950170-25-063831 · ownership.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,941,985 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.00 to $73.65 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 02, 2025 Filed May 6, 2025 00:28 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 18,480 | $72.52 | $1,340,145.58 |
DisclosureSEC source: 0000950170-25-063831 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,963,505 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $72.13 to $72.99 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:01 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 350 | $114.71 | $40,148.50 |
DisclosureSEC source: 0000950170-25-049790 · ownership.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,981,985 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F2 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:01 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 35,102 | $94.72 | $3,324,861.44 |
DisclosureSEC source: 0000950170-25-049790 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,982,335 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F2 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 21:07 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 1,974 | $60.83 | $120,084.14 |
DisclosureSEC source: 0000950170-25-045433 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 3,017,437 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $60.83 to $60.93 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:44 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 2,924 | $60.91 | $178,097.92 |
DisclosureSEC source: 0000950170-25-032740 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 3,019,411 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $60.83 to $61.045 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:44 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 350,000 | $0.00 Strike: $60.58 | $0.00 |
DisclosureSEC source: 0000950170-25-032740 · ownership.xml · derivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2035-02-28 F4 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:42 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 450,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000950170-24-090052 · ownership.xml · derivative · entry 4 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 450,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:42 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 259,583 | $38.67 | $10,038,074.61 |
DisclosureSEC source: 0000950170-24-090052 · ownership.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 539,228 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on July 31, 2024. The options subject to the net exercise were to expire on February 18, 2025. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:42 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 450,000 | $3.29 | $1,480,500.00 |
DisclosureSEC source: 0000950170-24-090052 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 798,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2024 Filed Feb 14, 2025 21:40 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 190,417 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-021329 · ownership.xml · nonDerivative · entry 4 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 3,022,335 F1 · kind: Transfer of shares without consideration to the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02. F2 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. F3 · ownership.nature: Due to an administrative error, prior reporting of the name of this trust has been corrected. The exact name of the trust, "Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02" was mistakenly identified as the "Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 01/29/02". Read SEC document |
| July 31, 2024 Filed Feb 14, 2025 21:40 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 190,417 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-021329 · ownership.xml · nonDerivative · entry 3 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:25 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 500,000 | $0.00 Strike: $23.01 | $0.00 |
DisclosureSEC source: 0000950170-24-014879 · ownership.xml · derivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2034-02-09 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 9, 2024 over a four-year period. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 500,000 | $0.00 Strike: $23.06 | $0.00 |
DisclosureSEC source: 0000899243-23-005173 · doc4.xml · derivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 13, 2023 over a four-year period. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 21:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 55,111 | $26.26 | $1,446,944.82 |
DisclosureSEC source: 0000899243-22-025827 · doc4.xml · nonDerivative · entry 4 BELANOFF JOSEPH K · CIK 0001286199 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 01/29/02 Disclosed balance after: 2,483,107 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2022, as amended. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $26.21 to $26.41. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F5 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 01/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 800,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-025827 · doc4.xml · derivative · entry 5 BELANOFF JOSEPH K · CIK 0001286199 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 800,000 shares Expires 2023-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.